Mitomycin Accord (Mitomycin)

Mitomycin is an antineoplastic antibiotic used in the treatment of solid tumors.

• Gastric carcinoma: improves tumor control and may extend survival.
• Pancreatic carcinoma: incorporated into combination regimens to reduce tumor burden.
• Bladder cancer: administered systemically or intravesically to achieve local tumor eradication.
• Other solid tumors: employed in selected cases to inhibit malignant cell growth.

• Mitomycin undergoes enzymatic reduction within tumor cells to generate a highly reactive alkylating species. This species creates covalent cross‑links between DNA strands, preventing strand separation and thereby blocking DNA synthesis and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly proliferating malignant cells.

Mitomycin may cause a range of adverse reactions during therapy.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset commonly reported.
• Myelosuppression: reduced white blood cells, neutrophils, and platelets.
• Fatigue: persistent tiredness during treatment.
• Mucositis: inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects

• Severe bone marrow suppression: profound pancytopenia requiring transfusion.
• Pulmonary toxicity: interstitial pneumonitis or fibrosis.
• Hemolytic‑uremic syndrome: acute kidney injury with hemolysis.

When using Mitomycin, clinicians should observe several safety measures.

• Renal function: assess baseline creatinine and monitor during therapy.
• Hematologic status: obtain a complete blood count before each dose.
• Pulmonary history: evaluate for pre‑existing lung disease.
• Pregnancy and lactation: avoid use unless benefits outweigh risks.
• Drug interactions: review concomitant medications for potential additive myelosuppression.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomycin can interact with other agents, requiring careful management.

Major Interactions (Avoid)

• Other alkylating agents: additive bone marrow toxicity.
• Radiation therapy: increased risk of severe tissue damage.
• Nephrotoxic drugs: heightened renal toxicity.

Moderate Interactions (Monitor Closely)

• Antifungal azoles: may affect drug metabolism.
• CYP450 inhibitors: potential increase in plasma levels.
• G‑CSF support agents: may mask myelosuppression.